Forbion Capital Partners raised about $50 million for a second fund to invest in health-care companies that are close to being sold.
The fund made its first investment in CircuLite Inc., a U.S. developer of devices to treat heart failure, the Dutch firm said in an e-mailed statement today.
Forbion’s first FCF 1 Co-Investment Fund, which raised 54 million euros ($72 million), has made six investments. One of those companies, BioVex Group Inc., was purchased by Amgen Inc. (AMGN) in January for as much as $1 billion. Another company in Forbion’s portfolio, Pathway Medical Technologies Inc., was sold in September to Bayer AG (BAYN) for $125 million, the firm said.
“We raised this second FCF 1 Co-Investment Fund in just a few weeks in difficult markets,” Sander Slootweg, a managing partner at Forbion, said in the statement.
To contact the reporter on this story: Kristen Hallam in London at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com